William Breen

Jan 15, 2025 | redjournal.org | William Breen

Get full text accessLog in, subscribe or purchase for full access. ReferencesGal, O ∙ Kotecha, RTip of the iceberg or the whole Titanic: Discrepant representation of glioblastoma on different imaging modalitiesInt J Radiat Oncol Biol Phys. 2025; 121:287-288Trifiletti, DM ∙ Milano, MT ∙ Redmond, KJ ... Treatment planning expansions in glioblastoma: How less can be moreInt J Radiat Oncol Biol Phys. 2023; 117:293-296Karschnia, P ∙ Dono, A ∙ Young, JS ...

Jul 13, 2024 | redjournal.org | Elizabeth L. McKone |William Breen |Nathan Foster

Memantine is standard in certain adults receiving brain radiation therapy (RT) to decrease cognitive impacts, but it is unknown whether pediatric patients can take, tolerate, and/or benefit from memantine. In this prospective single-arm feasibility study, we hypothesized that pediatric patients receiving central nervous system (CNS) RT would tolerate memantine with good adherence.

Aug 17, 2023 | nature.com | William Breen |Jason Young |Radhika Bansal |N. Nora Bennani |Jonas Paludo |Yucai Wang | +2 more

AbstractPET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T) infusion at two time points: pre-leukapheresis (pre-leuk) and pre-lymphodepletion chemotherapy (pre-LD). We hypothesized that changes in PET/CT between these time points predict outcomes after CAR-T.